Blockchain Registration Transaction Record

Soligenix Reports Q2 2025 Results and Advances Rare Disease Treatments

Soligenix announces Q2 2025 results, showcasing progress in rare disease treatments. Key milestones include Phase 2a results for psoriasis and CTCL therapies. Learn more.

Soligenix Reports Q2 2025 Results and Advances Rare Disease Treatments

This news is significant for patients with rare diseases and investors in the biopharmaceutical sector. Soligenix's progress in developing treatments for conditions like psoriasis, CTCL, and Behçet’s Disease represents potential new options for patients with limited treatment choices. The company's financial health and pipeline advancements also offer insights into the viability of investing in biotech firms focused on rare diseases, highlighting the intersection of healthcare innovation and investment opportunities.

BlockchainDetails
Contract Address0xeA2912a8DA1CD48401b10cB283585874d98098F4
Transaction ID0x4c7b15130beb2490ed1f20ea2f8efd39121403612bca642d081d517c69229375
Account0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20
Chainpolygon-main
NewsRamp Digital Fingerprintgold3ipq-eda7e6f59d30a7bc426402060a03440f